CLEC9A and neoplasm: Promisingly, the co‐delivery of αGalCer and tumor antigens to cDC1s using nanoparticle‐based vaccine covered with anti‐CLEC9A antibodies promotes antitumor responses both in vivo in mouse model and ex vivo from PBMC of melanoma patients.78